Inhibition of leukotriene C4 action reduces oxidative stress and apoptosis in cardiomyocytes and impedes remodeling after myocardial injury

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 3, 2011, Pages 570-577

  Becher, Ulrich M ^a   Ghanem, Alexander ^a   Tiyerili, Vedat ^a   Fürst, Dieter O ^b   Nickenig, Georg ^a   Mueller, Cornelius F H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Cys LT1 receptor; LTC4; MRP1; Myocardial injury; Oxidative stress

Indexed keywords

LEUKOTRIENE C4; MONTELUKAST; MULTIDRUG RESISTANCE PROTEIN 1; REACTIVE OXYGEN METABOLITE; RECOMBINANT LEUKOTRIENE C4; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VERLUKAST; ACETIC ACID DERIVATIVE; GLYCOPROTEIN P; QUINOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ECHOCARDIOGRAPHY; EMBRYO; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART VENTRICLE REMODELING; HEART WEIGHT; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LUMINESCENCE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION; WILD TYPE; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; ECHOGRAPHY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

MUS;

ACETATES; ANIMALS; APOPTOSIS; CELLS, CULTURED; ECHOCARDIOGRAPHY; HEART VENTRICLES; LEUKOTRIENE C4; MALE; MICE; MICE, TRANSGENIC; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; OXIDATIVE STRESS; P-GLYCOPROTEIN; QUINOLINES; REACTIVE OXYGEN SPECIES; VENTRICULAR REMODELING;

EID: 79551606403     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.11.013     Document Type: Article

References (32)

1. Brain S.D., Williams T.J. Leukotrienes and inflammation. Pharmacol Ther 1990, 46:57-66.
2. Woszczek G., Pawliczak R., Kowalski M.L. Leukotrienes as inflammation mediators. Postepy Hig Med Dosw 2003, 57:593-610.
3. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
4. Kruh G.D., Zeng H., Rea P.A., Liu G., Chen Z.S., Lee K., et al. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 2001, 33:493-501.
5. Kruh G.D., Belinsky M.G. The MRP family of drug efflux pumps. Oncogene 2003, 22:7537-7552.
6. Flens M.J., Zaman G.J., van der Valk P., Izquierdo M.A., Schroeijers A.B., Scheffer G.L., et al. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996, 148:1237-1247.
7. Wijnholds J., Evers R., van Leusden M.R., Mol C.A., Zaman G.J., Mayer U., et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 1997, 3:1275-1279.
8. Hirrlinger J., Konig J., Keppler D., Lindenau J., Schulz J.B., Dringen R. The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. J Neurochem 2001, 76:627-636.
9. Mueller C.F., Widder J.D., McNally J.S., McCann L., Jones D.P., Harrison D.G. The role of the multidrug resistance protein-1 in modulation of endothelial cell oxidative stress. Circ Res 2005, 97:637-644.
10. Mueller C.F., Wassmann K., Widder J.D., Wassmann S., Chen C.H., Keuler B., et al. Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export. Circulation 2008, 117:2912-2918.
11. Fleischmann B.K., Duan Y., Fan Y., Schoneberg T., Ehlich A., Lenka N., et al. Differential subunit composition of the G protein-activated inward-rectifier potassium channel during cardiac development. J Clin Invest 2004, 114:994-1001.
12. Roell W., Lewalter T., Sasse P., Tallini Y.N., Choi B.R., Breitbach M., et al. Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature 2007, 450:819-824.
13. Strehlow K., Rotter S., Wassmann S., Adam O., Grohe C., Laufs K., et al. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res 2003, 93:170-177.
14. Zhivotosky B., Orrenius S. Assessment of apoptosis and necrosis by DNA fragmentation and morphological criteria. Curr Protoc Cell Biol 2001, Chapter 18: Unit 18 3.
15. Roell W., Fan Y., Xia Y., Stoecker E., Sasse P., Kolossov E., et al. Cellular cardiomyoplasty in a transgenic mouse model. Transplantation 2002, 73:462-465.
16. Fletcher P.J., Pfeffer J.M., Pfeffer M.A., Braunwald E. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ Res 1981, 49:618-626.
17. Ghanem A., Troatz C., Elhafi N., Dewald O., Heeschen C., Nickenig G., et al. Quantitation of myocardial borderzone using reconstructive 3-D echocardiography after chronic infarction in rats: incremental value of low-dose dobutamine. Ultrasound Med Biol 2008, 34:559-566.
18. Yang X.P., Liu Y.H., Rhaleb N.E., Kurihara N., Kim H.E., Carretero O.A. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol 1999, 277:H1967-H1974.
19. Back M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther 2009, 23(1):41-48.
20. Mueller C.F., Becher M.U., Zimmer S., Wassmann S., Keuler B., Nickenig G. Angiotensin II triggers release of leukotriene C4 in vascular smooth muscle cells via the multidrug resistance-related protein 1. Mol Cell Biochem 2010, 333:261-267.
21. Payen L., Gao M., Westlake C., Theis A., Cole S.P., Deeley R.G. Functional interactions between nucleotide binding domains and leukotriene C4 binding sites of multidrug resistance protein 1 (ABCC1). Mol Pharmacol 2005, 67:1944-1953.
22. Riccioni G., Back M., Capra V. Leukotrienes and atherosclerosis. Curr Drug Targets 2010, 11(7):882-887.
23. Hakonarson H. Role of FLAP and PDE4D in myocardial infarction and stroke: target discovery and future treatment options. Curr Treat Options Cardiovasc Med 2006, 8:183-192.
24. De Caterina R., Zampolli A. From asthma to atherosclerosis-5-lipoxygenase, leukotrienes, and inflammation. N Engl J Med 2004, 350:4-7.
25. Javadov S., Karmazyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem 2007, 20:1-22.
26. Lefer A.M., Lefer D.J. Endothelial dysfunction in myocardial ischemia and reperfusion: role of oxygen-derived free radicals. Basic Res Cardiol 1991, 86(Suppl 2):109-116.
27. Aoshiba K., Yasui S., Nishimura K., Nagai A. Thiol depletion induces apoptosis in cultured lung fibroblasts. Am J Respir Cell Mol Biol 1999, 21:54-64.
28. Kyriakis J.M., Avruch J. Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays 1996, 18:567-577.
29. Funk C.D. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 2005, 4:664-672.
30. Kanaoka Y., Boyce J.A. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 2004, 173:1503-1510.
31. van den Bos E.J., Mees B.M., de Waard M.C., de Crom R., Duncker D.J. A novel model of cryoinjury-induced myocardial infarction in the mouse: a comparison with coronary artery ligation. Am J Physiol Heart Circ Physiol 2005, 289:H1291-H1300.
32. Lewis C.W., Atkins B.Z., Hutcheson K.A., Gillen C.T., Reedy M.C., Glower D.D., et al. A load-independent in vivo model for evaluating therapeutic interventions in injured myocardium. Am J Physiol 1998, 275:H1834-H1844.